G

GI Innovation Inc
KOSDAQ:358570

Watchlist Manager
GI Innovation Inc
KOSDAQ:358570
Watchlist
Price: 8 440 KRW -8.46% Market Closed
Market Cap: 373.9B KRW
Have any thoughts about
GI Innovation Inc?
Write Note

Operating Margin
GI Innovation Inc

-899.4%
Current
-3 044%
Average
-7.8%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-899.4%
=
Operating Profit
-42.8B
/
Revenue
4.8B

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
KR
GI Innovation Inc
KOSDAQ:358570
373.4B KRW
-899%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
310.3B USD
28%
US
Amgen Inc
NASDAQ:AMGN
141.6B USD
19%
US
Gilead Sciences Inc
NASDAQ:GILD
115.3B USD
38%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
102.4B USD
40%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
AU
CSL Ltd
ASX:CSL
134.4B AUD
26%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
77.3B USD
30%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
35.8B EUR
-22%
Country KR
Market Cap 373.4B KRW
Operating Margin
-899%
Country FR
Market Cap 6T USD
Operating Margin
-17 527%
Country US
Market Cap 310.3B USD
Operating Margin
28%
Country US
Market Cap 141.6B USD
Operating Margin
19%
Country US
Market Cap 115.3B USD
Operating Margin
38%
Country US
Market Cap 102.4B USD
Operating Margin
40%
Country US
Market Cap 94.1B EUR
Operating Margin
-370%
Country AU
Market Cap 134.4B AUD
Operating Margin
26%
Country US
Market Cap 77.3B USD
Operating Margin
30%
Country US
Market Cap 39.3B EUR
Operating Margin
-33%
Country NL
Market Cap 35.8B EUR
Operating Margin
-22%
No Stocks Found

GI Innovation Inc
Glance View

Market Cap
373B KRW
Industry
Biotechnology

GI Innovation, Inc. engages in the development of biopharmaceutical products. The company is headquartered in Seoul, Seoul and currently employs 88 full-time employees. The company went IPO on 2023-03-30. The firm is engaged in the business of generating revenue through license fees by technology transfer of new drug candidates in pre-clinical and early clinical stages. The core new drug pipeline includes products such as GI-101 immuno-oncology and GI-301 allergy treatment.

Intrinsic Value
9 532.34 KRW
Undervaluation 11%
Intrinsic Value
Price
G

See Also

Discover More
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-899.4%
=
Operating Profit
-42.8B
/
Revenue
4.8B
What is the Operating Margin of GI Innovation Inc?

Based on GI Innovation Inc's most recent financial statements, the company has Operating Margin of -899.4%.